Why the U.S. Neurology Clinical Trials Market Is Set to Nearly Double by 2034 — and What It Means for Pharma and CRO Leaders With roughly 7 million Americans living with Alzheimer's disease alone, the pressure to bring new neurological therapies to market has rarely been higher — and the U.S. research infrastructure built to support that effort keeps expanding. According to Polaris...